RedHill Biopharma Ltd. (RDHL)

NASDAQ: RDHL · IEX Real-Time Price · USD
0.381
+0.015 (4.12%)
At close: Jun 24, 2024, 3:56 PM
0.374
-0.007 (-1.84%)
After-hours: Jun 24, 2024, 6:05 PM EDT
4.12%
Market Cap 11.93M
Revenue (ttm) 6.53M
Net Income (ttm) 23.92M
Shares Out 31.87M
EPS (ttm) 4.00
PE Ratio 0.09
Forward PE 1,428.57
Dividend n/a
Ex-Dividend Date n/a
Volume 208,099
Open 0.353
Previous Close 0.366
Day's Range 0.353 - 0.390
52-Week Range 0.257 - 3.280
Beta 3.56
Analysts n/a
Price Target n/a
Earnings Date Aug 15, 2024

About RDHL

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiat... [Read more]

Sector Healthcare
Founded 2009
Employees 53
Stock Exchange NASDAQ
Ticker Symbol RDHL
Full Company Profile

Financial Performance

Financial Statements

News

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

New Chinese patent notice of allowance issued covering opaganib in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response [1] . Provides protection...

21 days ago - PRNewsWire

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035 and adds to opaganib's strong global intell...

7 weeks ago - PRNewsWire

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat)1  for early COVID-19 outpatient treatment, funded through non-dilutive external sources, i...

2 months ago - PRNewsWire

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base   Focused externally funded R...

2 months ago - PRNewsWire

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

TEL AVIV, Israel and RALEIGH, N.C. , April 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.

2 months ago - PRNewsWire

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia 1  as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia protection until February 12, 2034 This...

3 months ago - PRNewsWire

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by ASPR/BARDA and NIH/NIAID, in collaboration with ...

Other symbols: GILD
3 months ago - PRNewsWire

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ion...

Other symbols: AMGNGILD
4 months ago - PRNewsWire

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

TEL AVIV, Israel and RALEIGH, N.C., Jan. 26, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.

5 months ago - PRNewsWire

RedHill Biopharma Announces $8 Million Registered Direct Offering

TEL AVIV, Israel and RALEIGH, N.C. , Jan. 25, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.

5 months ago - PRNewsWire

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

USPTO issues new patent covering Talicia [1] as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI) [2] , supporting Talicia protection until May 2042 The patent is supporte...

5 months ago - PRNewsWire

RedHill Biopharma shares jump as Ebola treatment shows promise

RedHill Biopharma Ltd. American depositary receipts RDHL, +8.20% climbed 10% premarket on Wednesday after the company said two of its experimental drugs, when individually combined with remdesivir, sh...

6 months ago - Market Watch

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly improving potency while maintaining cell viabil...

6 months ago - PRNewsWire

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

TEL AVIV, ISRAEL and RALEIGH, N.C., Dec. 12, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.

6 months ago - PRNewsWire

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

The new non-dilutive external funding, additional to the previously announced U.S. Government non-dilutive funding, now covers the entirety of the RHB-107 (upamostat) [1]  arm of the ACESO PROTECT ada...

7 months ago - PRNewsWire

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

Stocks are poised for an upbeat finish to the best month of gains for 2023, as the fever pitch around Fed rate cuts next year grows. It's all teeing up nicely for that Santa rally, maybe.

7 months ago - Market Watch

RedHill Biopharma (RDHL) gained 216% after FDA approvals: Buy Now!

RedHill Biopharma Ltd (NASDAQ: RDHL) just received an exclusive licence for the commercialisation of Talicia. The drug is used to treat Helicobacter Pylori infections, commonly known as H- Pylori.

7 months ago - Invezz

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

The U.S. FDA has granted five years' market exclusivity for Talicia under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, as recommended by...

7 months ago - PRNewsWire

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

TEL AVIV, Israel & RALEIGH, N.C. , Nov. 14, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.

7 months ago - PRNewsWire

RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study

- Novel, oral opaganib, delivered a statistically significant increase in survival time (at 150 mg/kg BID) in a U.S. Army-funded in vivo Ebola virus study - Opaganib is believed to be the first host-d...

9 months ago - PRNewsWire

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

TEL AVIV, Israel & RALEIGH, N.C. , Sept. 22, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.

9 months ago - PRNewsWire

RedHill Announces FDA sNDA Approval for Talicia®

FDA approves supplemental new drug application (sNDA) for Talicia, changing dosing to a simplified three times daily (TID) regimen, which may support increased patient adherence and treatment outcomes...

10 months ago - PRNewsWire

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

USPTO issues Notice of Allowance for a new opaganib patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib protection until October 2035 Additionally, E...

10 months ago - PRNewsWire

RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights

RHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment; The 300-patient Phase 2 study received FDA clearance an...

11 months ago - PRNewsWire

RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.

RedHill's partner, Gaelan Medical, part of the Ghassan Aboud Group (GAG), receives marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia Gaelen placed a meaningful init...

11 months ago - PRNewsWire